CDX-622

N/A

Report date: 2026/02/10 20:00:22

Base Information

Drug NameCDX-622
Drug Alias NameTSLP/SCF bispecific antibodyCDX-622
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Thymic stromal lymphopoietinAnti-Stem cell growth factor receptor
TargetsThymic stromal lymphopoietinStem cell growth factor receptor
Therapy Area/IndicationsInflammationFibrosisHypersensitivity +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelldex Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelldex TherapeuticsCelldex Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationFibrosisHypersensitivity +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A